Compare Global E Online Ltd (GLBE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs Merck & Co., Inc. — how do they compare? Global E Online Ltd trades at $38.2 (market cap $6.55B), while Merck & Co., Inc. trades at $127.13 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 46.6× Global E Online Ltd's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| GLBE | MRK | |
|---|---|---|
Market Cap | $6.55B | $305.29B |
Sector | Technology | Health |
52-Week High | $41.59 | $129.52 |
52-Week Low | $27.54 | $77.60 |
Enterprise Value | $6.02B | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.43, down 0.84% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with 33% revenue growth and raised its full-year outlook. Recent acquisition of Passport aims to enhance logistics capabilities. Valuation ratios are elevated with a P/E of 58.18, reflecting high growth expectations.
Outlook remains positive driven by merchant expansion and cross-border e-commerce growth, but high valuation poses a risk if growth slows. Analyst consensus is unanimously bullish with a $38 price target, though recent insider sales and mixed quarterly EPS performance warrant monitoring.
MRK's stock trades at $128.08, up 6.02% over the past day, reflecting strong momentum. The technical outlook is bullish based on moving averages, with key support at $121 and resistance at $126. Fundamentally, the company reported $65.01B in 2025 revenue with a net income margin of 13.59%, and recent earnings beats in Q3 2025 and Q4 2025 highlight operational strength. The pending acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, signaling strategic growth initiatives.
The investment outlook for MRK is positive, supported by analyst consensus with a $137.30 price target and 67.57% buy ratings. Key opportunities include robust profitability and pipeline expansion via M&A, while risks involve rising debt levels and competitive pressures in the pharmaceutical sector. Earnings growth and successful integration of acquisitions are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
